Exscientia, specialists in artificial intelligence (AI) driven drug discovery, is pleased to announce the appointment of Alex Snow to its Board of Directors as Deputy Chairman. He brings significant strategic development and financial experience to the board.
Snow is an experienced investor, banker and entrepreneur, having previously founded Oxford Sciences Innovation (OSI) and raised more than £600 million to commercialise world-leading science originating at Oxford University.
Prior to OSI, Snow spent 20 years in investment banking and fund management, most recently as CEO of the hedge fund Lansdowne Partners. He was also the founder and CEO of Evolution Group, a UK investment banking and securities firm, which was sold to Investec Bank for £232 million in 2011.
Andrew Hopkins, Chairman and CEO of Exscientia, said: “We are delighted to welcome Alex to Exscientia. Alex brings deep investor knowledge and unique entrepreneurial skills to the board. He has a passion for translating-cutting edge science into long-term, tangible value.”
“We are confident that his extensive experience in the investment community and wide networks will be invaluable in supporting the company’s strategy for growth. We have made great progress in 2017, having announced collaborations with GSK, Sanofi and a significant investment from Evotec; with Alex joining us, we look forward to an exciting year in 2018.”
Snow said: “Exscientia is a truly exciting company with the potential to be a game-changer in the pharma industry, as a tech company that discovers drugs. There is growing realisation of the disruptive potential of AI in pharma and Exscientia is leading the field.”
“With the successes so far achieved, we are beginning to see exciting evidence of acceleration of the discovery of new medicines through application of its unique AI platform. The company has signed some impressive deals to date and is poised to move to the next phase of its development. I am very much looking forward to making my contribution to building a great company.”